Overview
- 94 inspections across 69 sites are on record.
- 269 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2018-02-06.
At a glance
Inspections
94
Sites
69
Observations
269
Career since
Sep 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Hanlim Pharm Co. Ltd. | 6 Feb 2018 | Human Drugs | View 483 → |
| Shanghai Ziyuan Pharmaceutical Co., Ltd. | 28 Oct 2016 | Human Drugs | |
| Ningbo Pulisi Daily Chemical Products Co., Ltd | 21 Oct 2016 | Human Drugs | View 483 → |
| WES Pharma Inc. | 6 Nov 2015 | Human Drugs | View 483 → |
| Merck Sharp & Dohme LLC | 21 Aug 2015 | Human Drugs | On file |
Sites inspected
Hanlim Pharm Co. Ltd.Yongin, Korea (the Republic of)1 insp.
Shanghai Ziyuan Pharmaceutical Co., Ltd.Shanghai, China1 insp.
Ningbo Pulisi Daily Chemical Products Co., LtdYuyao City, China1 insp.
WES Pharma Inc.Westminster, United States1 insp.
Merck Sharp & Dohme LLCElkton, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Ernest Bizjak9 shared
Nebil A Oumer7 shared
Brooke K Higgins6 shared
Tajah L Blackburn3 shared
Chiang Syin3 shared
Julie A Silberberg3 shared
Stacey A Priest3 shared
Don H Bark3 shared
Edward P Potter3 shared
Steven P Donald2 shared
Full investigator report
Get the verbatim findings behind Rachel C Harrington's 269 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site